Microbot Medical Secures Additional Protection for the One & Done Guidewire Technology with another Notice of Patent Allowanc...
June 04 2021 - 7:00AM
Global patent jurisdictions continue to recognize Microbot Medical
Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire
technology, as the Israel Intellectual Property Office has issued a
Notice of Allowance (NOA). The allowed application covers
Microbot’s double guidewire technology that has been granted in
Europe, Japan and now Israel. Globally, Microbot Medical holds a
total of 42 patents issued/allowed and 23 pending patent
applications.
“The One & Done is an integral part of the
future development portfolio of LIBERTY, and will ensure we
maintain sustainable competitive advantage,” commented Harel Gadot,
CEO, President and Chairman. “We are very pleased that our
continued focus on innovation is reflected in our differentiated
technology IP portfolio that has been recognized by multiple global
patent offices.”
The allowed claims in this patent cover a double
guidewire comprising a first hollow guidewire (outer tube) and a
second guidewire (inner tube), each guidewire is preshaped to
impart a lateral deflection to its distal portion. An adjuster
mechanism is operable to displace the inner tube longitudinally
relative to the outer tube between at least three states. Each such
state displaces the deflection of the outer and inner tubes
relative to each other, thereby adjusting the properties of
curvature and stiffness of the distal portion of the entire double
guidewire.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY and SCS, the outcome of its studies to evaluate
LIBERTY, SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024